Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) EPS (Weighted Average and Diluted) (2016 - 2023)

Ekso Bionics Holdings has reported EPS (Weighted Average and Diluted) over the past 11 years, most recently at -$0.33 for Q1 2023.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 8.33% to -$0.33 in Q1 2023 year-over-year; TTM through Mar 2023 was -$1.13, a 25.56% decrease, with the full-year FY2022 number at -$1.16, down 31.82% from a year prior.
  • EPS (Weighted Average and Diluted) reached -$0.33 in Q1 2023 per EKSO's latest filing, down from -$0.24 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.04 in Q3 2019, with the low at -$1.88 in Q2 2020.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.26 (2021), against an average of -$0.36.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 136.36% in 2019, then tumbled 1600.0% in 2021.
  • Tracing EKSO's EPS (Weighted Average and Diluted) over 5 years: stood at $0.04 in 2019, then tumbled by 1175.0% to -$0.43 in 2020, then surged by 39.53% to -$0.26 in 2021, then rose by 7.69% to -$0.24 in 2022, then tumbled by 37.5% to -$0.33 in 2023.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.33, -$0.24, and -$0.33 for Q1 2023, Q4 2022, and Q3 2022 respectively.